Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Receives 2025 Charles A. Sanders, MD, Partnership Award From the Foundation for the National Institutes of Health

Rhea-AI Summary

Alexandria Real Estate Equities (NYSE: ARE) and Alexandria Venture Investments received the 2025 Charles A. Sanders, MD, Partnership Award from the Foundation for the National Institutes of Health on October 22, 2025.

The award recognizes Alexandria's leadership in launching a public-private precision medicine partnership, MAP-D (Multi-Level Assessment & Phenotyping in Depression), developed with NIMH, FDA, VA, research institutions, industry partners, and patient advocates. MAP-D completed its critical design phase and targets a Phase 1 launch in May 2026 to assemble a comprehensive depression dataset and validate biomarkers to guide individualized treatment.

Positive

• FNIH award received on October 22, 2025
• MAP-D completed critical design phase
• Phase 1 study targeted to launch May 2026

Negative

• Clinical study not yet started; results and timeline outcomes are pending

Insights

Strategic partnerships analyst

Alexandria's award reflects a material public-private partnership that advances a large precision-medicine depression study launching May 2026.

The recognition highlights **Alexandria Real Estate Equities** and **Alexandria Venture Investments** for leading the public-private MAP-D initiative with the FNIH, NIH, FDA, and VA. The company acted as catalyst and convenor, securing cross-sector engagement and funding to reach the study's design-phase completion.

The effort's business mechanism lies in enabling and coordinating large-scale research infrastructure and data access rather than direct drug development, which can raise Alexandria's strategic profile and strengthen its ecosystem relationships. Key dependencies include continued funding, partner participation, and successful transition from design to the planned first-phase launch in May 2026.

Monitor the actual study launch in May 2026, confirmations of committed funding amounts, and any formal data‑sharing agreements that define access and IP terms over the next 6–12 months.

Clinical research program advisor

MAP-D reached design completion and targets a May 2026 first phase to build a large, shared depression biomarker dataset.

The program aims to assemble comprehensive phenotyping and biomarker data to classify depression subtypes and validate measures, starting with a long-term clinical study. The milestone reported is the completion of a critical design phase, which is necessary before patient enrollment and data collection begin.

Risks and dependencies stated include coordination with federal agencies and external research institutions and securing implementation funding. Concrete near-term items to watch are the planned first-phase start in May 2026 and statements detailing sample size, endpoints, and data access rules; these items will determine the study's scientific and translational value.

This prestigious award recognizes Alexandria's leadership in initiating and catalyzing a groundbreaking public-private partnership with the FNIH that leverages precision medicine to unravel the complexities of depression and drive a paradigm shift in treatment

PASADENA, Calif., Oct. 22, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured, and pioneering owner, operator, and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, and Alexandria Venture Investments, the company's strategic venture platform, are being honored by the Foundation for the National Institutes of Health (FNIH) with a 2025 Charles A. Sanders, MD, Partnership Award this evening in Washington, D.C. The prestigious award recognizes Alexandria's significant contributions to the FNIH's work in accelerating biomedical innovation, epitomized by the company's leadership in catalyzing a mission-critical public-private partnership with the FNIH to build a precision medicine framework for depression to address the urgent need for new, more effective medicines for patients. The first-of-its-kind initiative is being developed in collaboration with the National Institute of Mental Health, the U.S. Food and Drug Administration, and the U.S. Department of Veterans Affairs, as well as leading research institutions, leading-edge life science entities, and patient advocates. The bold program aims to pave the way for a future where major depressive disorder is effectively treated at an individual level, rather than by a one-size-fits-all approach.

"We are very honored to receive the FNIH Partnership Award. This recognition affirms our leadership at the vanguard of the life science ecosystem and our consequential role in spearheading impactful collaborations that improve human health — notably by advancing solutions to our nation's unprecedented mental health crisis," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "In the United States each year, major depressive disorder affects more than 21 million adults, nearly one-third of whom suffer from treatment-resistant depression. For families, the cost is immeasurable, and for society, the economic burden exceeds $380 billion annually, rivaling the nation's largest drivers of chronic disease-related health care spending. These staggering statistics are a call to action highlighting the urgent need for better treatment options. We are immensely proud of our role in initiating and catalyzing this mission-critical FNIH initiative."

Alexandria has and continues to engage cross-sector partners and help secure funding from across its life science ecosystem, both critical endeavors to launching and implementing the initiative now officially known as Multi-Level Assessment & Phenotyping in Depression (MAP-D). To date, the MAP-D program has successfully completed its critical design phase — a foundational milestone in developing a long-term transformative clinical study to identify and validate biomarkers for depression. The study's first phase is targeted to launch in May 2026 to coincide with Mental Health Awareness Month.

In the near term, the study aims to create one of the most comprehensive depression research datasets ever assembled, validate new ways to measure and track depression, and open new opportunities for collaboration and therapeutic innovation. Over time, MAP-D's goal is to deliver a clearer classification of depression subtypes, identify biomarkers to guide treatment decisions, and equip clinicians with practical tools to match patients to the care that will help them most.

Among its critical objectives, the FNIH public-private partnership will strive to make data broadly accessible to qualified researchers, foster transparency, accelerate scientific progress, and expand the study's impact to other serious mental illnesses. To learn more, visit the FNIH program page.

About Alexandria Real Estate Equities, Inc. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2025, Alexandria has a total market capitalization of $25.7 billion and an asset base in North America that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction and one 100% pre-leased committed near-term project expected to commence construction in the next year. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's impact on the development of novel treatments and cures and on human health and well-being; Alexandria's thought leadership, collaborations, investments, and progress relating to the treatment of depression; and the goals and efforts of the MAP-D program. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. 

CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@are.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-incalexandria-venture-investments-receives-2025-charles-a-sanders-md-partnership-award-from-the-foundation-for-the-national-institutes-of-health-302590575.html

SOURCE Alexandria Real Estate Equities, Inc.

FAQ

What award did Alexandria (NYSE: ARE) receive on October 22, 2025?

Alexandria received the 2025 Charles A. Sanders, MD, Partnership Award from the Foundation for the National Institutes of Health.

What is MAP-D and when will Alexandria's MAP-D Phase 1 launch?

MAP-D is Multi-Level Assessment & Phenotyping in Depression; Phase 1 is targeted to launch in May 2026.

Which agencies are partners in Alexandria's MAP-D public-private program?

MAP-D is developed with the National Institute of Mental Health, FDA, Department of Veterans Affairs, research institutions, industry partners, and patient advocates.

How could MAP-D affect Alexandria shareholders (NYSE: ARE)?

The program highlights Alexandria's role in life-science ecosystem building and may enhance strategic partnerships and long-term asset relevance.

What are MAP-D's near-term research goals announced by Alexandria?

Near-term goals include assembling a comprehensive depression dataset, validating measurement methods, and identifying candidate biomarkers for treatment guidance.

Does the press release disclose MAP-D funding amounts or study outcomes?

No; the announcement notes cross-sector funding engagement but does not disclose funding amounts or study results.